先了解公司主体
公司基本信息
- 公司主体
- FUJIFILM Biotechnologies
- 总部 / 主要办公地点
- Morrisville, North Carolina ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗
- 资本 / 归属状态
- 集团子公司 / 业务平台FUJIFILM Group ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗ ↗
资料复查:2026-11-05 · 字段保留各自的来源日期;未披露不等于零,早期或历史事件不代表最新融资,资助及并购与股权融资分开。
疾病标签由已收录文字提及匹配,须逐项目核查。
技术、项目与证据
生物药生化、生物物理、效价及GMP分析服务
综合CRO/CDMO分析服务
未收录独立项目明细,请核对下方原始来源。
相关资讯与文献
以下按公司名称匹配,属于检索线索;同名主体和交易角色需查原文确认。
同领域阅读(并非公司动态)
Communications Chemistry
《Communications Chemistry》研究报道RaPiD-mAb-MS,将微孔板制样与直接进样质谱结合进行抗体肽图分析。原始摘要称,约1.5—2小时可分析96个样品,常规序列覆盖率超过95%,应用涉及28种抗体、2,000余份样品;比较涵盖多种修饰与序列变异,更广泛的方法适用性仍需评估。
U.S. Food and Drug Administration
FDA于11月2日宣布细胞与基因治疗效价保障最终指南,将工艺设计、物料与过程控制、过程检测及批放行效价分析纳入整体策略,强调产品特异、基于风险的全生命周期保障。该文件为最终指南,不是对某个治疗产品的批准。
mAbs
这篇行业观点将原生质谱定位为现有生物药表征方法的补充,讨论完整组装体、结合、化学计量与异质性,并指出通量、灵敏度、自动化和可及性限制。作者强调与分析流程整合,而非全面替代已有方法。
一起研究这家公司
讨论对已登录会员开放;个人备注与公开公司资料分开保存。
登录参与讨论来源与待核实问题
- 公司级服务记录,不代表自有药物管线。实验室资质与项目适用性需分别确认。
- Analytical Service GMP | Analytical Services | FUJIFILM ↗FUJIFILM Biotechnologies ·
- FUJIFILM Biotechnologies | LinkedIn ↗FUJIFILM Biotechnologies ·
- Elucidation of Structure ↗FUJIFILM Biotechnologies ·
- Your CDMO Partner FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
- Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions - FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
- Building Trust Through Our Partners for Life Strategy - FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
- FUJIFILM Biotechnologies is on a mission to become the leading and most trusted CDMO in the world. Through its ‘Partners for Life’ vision, driven by three core pillars — people first, transformative science and innovation, and unprecedented delivery — the company is reshaping how global partnerships are built on trust and transparency, ensuring reliable and impactful outcomes for both clients and patients. The company’s paradigm shifting kojoX™ operating philosophy and modular, harmonized ecosystem enables seamless scalability and efficiency, allowing companies to start small and quickly scale up, addressing critical biopharma challenges like limited global manufacturing capacity and inefficiencies in the supply chain. Every day, FUJIFILM Biotechnologies is making a difference for patients around the world by fostering global partnerships based on trust, not transactions. The company aligns with clients’ long-term goals to build collaborative, transparent partnerships that prioritize patient outcomes and drive continuous innovation. In this conversation with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D., President and CEO Lars Petersen explains how, by investing in state-of-the-art facilities and building a people-first culture, FUJIFILM Biotechnologies is positioning itself as the future of biopharmaceutical manufacturing. ↗FUJIFILM Biotechnologies ·
- Fujifilm Launches Bioethics Advisory Committee to Guide Ethical Decision-Making Across Life Sciences and Healthcare Businesses in the Americas - FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
- FUJIFILM Biotechnologies Unveils Biomanufacturing and Process Development Expansion in the United Kingdom - FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
- Voyager Therapeutics Strategic Manufacturing Collaboration - FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
- FUJIFILM Biotechnologies Transitions Leadership to Drive Next Phase of Operational Excellence - FUJIFILM Biotechnologies ↗FUJIFILM Biotechnologies ·
收录不等于背书或合作方质量认证。公司声明、临床证据与具体服务能力分别评估。